{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:37:13Z","timestamp":1793839033891,"version":"4.6.1"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>The landscape for treatment of rheumatic diseases is ever evolving, with several new drugs recently approved across diseases and more in the pipeline. This timely review aims to highlight the latest literature on long-term safety profiles of salient established and emerging biologic (b) and targeted synthetic (ts) disease modifying antirheumatic drugs (DMARDs).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>The risk of infection remains elevated with the use of most b and tsDMARDs, with specifically risk of hepatitis B reactivation with rituximab and zoster infection with JAK inhibitors (JAKi). The results of the ORAL surveillance trial led to new black box warnings for JAKi and evoked critical risk-benefit discussions surrounding JAKi and DMARDs overall.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Such well conducted trials are needed to gather long term comparative safety data of DMARDs. In the interim, real world observational studies also have a role to play in our understanding of long-term drug safety, provided that detailed attention is paid to minimize biases inherent in observational studies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000995","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T11:16:26Z","timestamp":1703157386000},"page":"113-119","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Long-term safety of biologic and targeted synthetic disease modifying drugs in rheumatology"],"prefix":"10.1097","volume":"36","author":[{"given":"Kaia","family":"Barth","sequence":"first","affiliation":[{"name":"Fellow, Division of Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsimrat","family":"Gill","sequence":"additional","affiliation":[{"name":"Medical Student, Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namrata","family":"Singh","sequence":"additional","affiliation":[{"name":"Assistant Professor, Division of Rheumatology"},{"name":"Adjunct Assistant Professor, Department of Epidemiology, University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,12,20]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMra2103726","article-title":"Rheumatoid arthritis - common origins, divergent mechanisms","volume":"388","author":"Gravallese","year":"2023","journal-title":"N Engl J Med"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/art.40017","article-title":"Rheumatoid arthritis and risk of malignant lymphoma: is the risk still increased?","volume":"69","author":"Hellgren","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1136\/ard-2022-223636","article-title":"Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study","volume":"82","author":"Huss","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1093\/rheumatology\/keab570","article-title":"Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice","volume":"61","author":"Huss","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/BOR.0b013e3282fa74f7","article-title":"Association of infections and tuberculosis with antitumor necrosis factor alpha therapy","volume":"20","author":"Patkar","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1136\/ard-2022-223302","article-title":"Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis","volume":"82","author":"Solomon","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s40744-019-00183-6","article-title":"Risk of malignancies in patients with rheumatoid arthritis treated with rituximab: analyses of global postmarketing safety data and long-term clinical trial data","volume":"7","author":"Emery","year":"2020","journal-title":"Rheumatol Ther"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/ard-2022-223762","article-title":"Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme","volume":"82","author":"Frisell","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/annrheumdis-2021-220418","article-title":"Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry","volume":"80","author":"Sparks","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"152149","DOI":"10.1016\/j.semarthrit.2022.152149","article-title":"Rituximab is associated with worse COVID-19 outcomes in patients with rheumatoid arthritis: A retrospective, nationally sampled cohort study from the U.S. National COVID Cohort Collaborative (N3C)","volume":"58","author":"Singh","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"R14-20250526","article-title":"Immunomodulators and risk for breakthrough infection after third COVID-19 mRNA vaccine among patients with rheumatoid arthritis: a cohort study","author":"Schiff","year":"2023","journal-title":"medRxiv"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1080\/17460441.2022.2093852","article-title":"Lessons learned from the preclinical discovery and development of sarilumab for the treatment of rheumatoid arthritis","volume":"17","author":"Maioli","year":"2022","journal-title":"Expert Opin Drug Discov"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/annrheumdis-2018-214326","article-title":"Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden","volume":"78","author":"Gron","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.semarthrit.2019.03.002","article-title":"Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: a multidatabase cohort study","volume":"49","author":"Kim","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/annrheumdis-2021-221640","article-title":"Persistence and effectiveness of the IL-12\/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study","volume":"81","author":"Gossec","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s12026-023-09366-4","article-title":"Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: a meta-analysis based on randomized controlled trials","volume":"71","author":"Huang","year":"2023","journal-title":"Immunol Res"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"1124628","DOI":"10.3389\/fphar.2023.1124628","article-title":"IL-17 inhibitor-associated inflammatory bowel disease: a study based on literature and database analysis","volume":"14","author":"Deng","year":"2023","journal-title":"Front Pharmacol"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/14740338.2021.1960981","article-title":"Gastroenterological safety of IL-17 inhibitors: a systematic literature review","volume":"21","author":"Caron","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"adv00648","DOI":"10.2340\/actadv.v102.175","article-title":"Global risk of bacterial skin infections and herpesviridae infections with ustekinumab, secukinumab, and tumour necrosis factor-alpha inhibitors: spontaneous reports of adverse drug reactions from the World Health Organization Pharmacovigilance Center","volume":"102","author":"Davidson","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/rheumatology\/keab522","article-title":"Risk of major adverse cardiovascular events in patients initiating biologics\/apremilast for psoriatic arthritis: a nationwide cohort study","volume":"61","author":"Pina Vegas","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1111\/bcp.15581","article-title":"Potential cerebrovascular accident signal for risankizumab: a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS)","volume":"89","author":"Woods","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"e683","DOI":"10.1111\/jdv.18830","article-title":"The cardiometabolic safety of interleukin 23 versus interleukin 17 inhibitors in psoriasis: a large-scale global cohort study","volume":"37","author":"Kridin","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R26-20250526","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X231186874","article-title":"Efficacy and safety of abatacept in patients with rheumatoid arthritis with previous malignancy","volume":"15","author":"Kunishita","year":"2023","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"R27-20250526","first-page":"1882","article-title":"Analysis of efficacy and safety of abatacept for rheumatoid arthritis: systematic review and meta-analysis","volume":"41","author":"Mohamed Ahamada","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1093\/rheumatology\/kez604","article-title":"Abatacept in rheumatoid arthritis and the risk of cancer: a world observational postmarketing study","volume":"59","author":"de Germay","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13075-023-03067-x","article-title":"Safety outcomes in patients with rheumatoid arthritis treated with abatacept: results from a multinational surveillance study across seven European registries","volume":"25","author":"Dominique","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"e780","DOI":"10.1002\/iid3.780","article-title":"Risk of hepatitis B reactivation in HBsAg-\/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: A meta-analysis","volume":"11","author":"Hong","year":"2023","journal-title":"Immun Inflamm Dis"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1080\/1744666X.2023.2249237","article-title":"JAK inhibitors and black box warnings: what is the future for JAK inhibitors?","volume":"19","author":"Tokareva","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/ard-2022-222259","article-title":"Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance","volume":"82","author":"Charles-Schoeman","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.1038\/s41598-022-10777-w","article-title":"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database","volume":"12","author":"Hoisnard","year":"2022","journal-title":"Sci Rep"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ard-2022-223050","article-title":"Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis","volume":"82","author":"Molander","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/acr2.11479","article-title":"Cardiovascular and venous thromboembolic risk with janus kinase inhibitors in immune-mediated inflammatory diseases: a systematic review and meta-analysis of randomized trials","volume":"4","author":"Maqsood","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/acr.20371","article-title":"Systematic review and meta-analysis: antitumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis","volume":"63","author":"Barnabe","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/ard-2022-223715","article-title":"Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance","volume":"82","author":"Kristensen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/art.42250","article-title":"Tofacitinib and risk of malignancy: results from the safety of tofacitinib in routine care patients with rheumatoid arthritis (STAR-RA) study","volume":"74","author":"Khosrow-Khavar","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/RHU.0000000000001804","article-title":"Risk of cardiovascular and venous thromboembolic events associated with janus kinase inhibitors in rheumatoid arthritis: a systematic review and network meta-analysis","volume":"28","author":"Alves","year":"2022","journal-title":"J Clin Rheumatol"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1136\/ard-2023-223916","article-title":"Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme","volume":"82","author":"Fleischmann","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R41-20250526","first-page":"275","article-title":"Efficacy and safety of upadacitinib in patients with psoriatic arthritis: 2-year results from the phase 3 SELECT-PsA 1 study","volume":"10","author":"McInnes","year":"2023","journal-title":"Rheumatol Ther"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(22)01212-0","article-title":"Upadacitinib for the treatment of active nonradiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Deodhar","year":"2022","journal-title":"Lancet"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1136\/annrheumdis-2021-221051","article-title":"Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6\u200ayears","volume":"81","author":"Winthrop","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"996662","DOI":"10.3389\/fimmu.2022.996662","article-title":"Evaluation of anifrolumab safety in systemic lupus erythematosus: a meta-analysis and systematic review","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/art.42392","article-title":"A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus","volume":"75","author":"Kalunian","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1177\/10600280231161592","article-title":"Avacopan for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis","volume":"57","author":"Alihosseini","year":"2023","journal-title":"Ann Pharmacother"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000995","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:16:01Z","timestamp":1748294161000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,20]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000995","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,20]]}}}